These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 22437111)
21. The pharmacology of cannabinoid receptors and their ligands: an overview. Pertwee RG Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099 [TBL] [Abstract][Full Text] [Related]
22. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. Merighi S; Simioni C; Gessi S; Varani K; Borea PA Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600 [TBL] [Abstract][Full Text] [Related]
23. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice. Cluny NL; Keenan CM; Duncan M; Fox A; Lutz B; Sharkey KA J Pharmacol Exp Ther; 2010 Sep; 334(3):973-80. PubMed ID: 20571060 [TBL] [Abstract][Full Text] [Related]
24. 5-Sulfonyl-benzimidazoles as selective CB2 agonists. Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887 [TBL] [Abstract][Full Text] [Related]
25. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146 [TBL] [Abstract][Full Text] [Related]
26. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives. Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813 [TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel class of selective human CB1 inverse agonists. Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560 [TBL] [Abstract][Full Text] [Related]
28. Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands. Nevalainen T Curr Med Chem; 2014; 21(2):187-203. PubMed ID: 24164198 [TBL] [Abstract][Full Text] [Related]
29. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913 [TBL] [Abstract][Full Text] [Related]
30. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Svízenská I; Dubový P; Sulcová A Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858 [TBL] [Abstract][Full Text] [Related]
31. Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists. Saari R; Törmä JC; Nevalainen T Bioorg Med Chem; 2011 Jan; 19(2):939-50. PubMed ID: 21215643 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB(1) and CB(2) receptors. Fan Y; Hooker BA; Garrison TR; El-Kouhen OF; Idler KB; Holley-Shanks RR; Meyer MD; Yao BB Eur J Pharmacol; 2011 Jun; 659(2-3):161-8. PubMed ID: 21458448 [TBL] [Abstract][Full Text] [Related]
33. Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists. Manera C; Saccomanni G; Adinolfi B; Benetti V; Ligresti A; Cascio MG; Tuccinardi T; Lucchesi V; Martinelli A; Nieri P; Masini E; Di Marzo V; Ferrarini PL J Med Chem; 2009 Jun; 52(12):3644-51. PubMed ID: 19435366 [TBL] [Abstract][Full Text] [Related]
34. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Han KH; Lim S; Ryu J; Lee CW; Kim Y; Kang JH; Kang SS; Ahn YK; Park CS; Kim JJ Cardiovasc Res; 2009 Dec; 84(3):378-86. PubMed ID: 19596672 [TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain. Yang SW; Smotryski J; Matasi J; Ho G; Tulshian D; Greenlee WJ; Brusa R; Beltramo M; Cox K Bioorg Med Chem Lett; 2011 Jan; 21(1):182-5. PubMed ID: 21115245 [TBL] [Abstract][Full Text] [Related]
36. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177 [TBL] [Abstract][Full Text] [Related]
37. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Sterin-Borda L; Del Zar CF; Borda E Biochem Pharmacol; 2005 Jun; 69(12):1705-13. PubMed ID: 15885656 [TBL] [Abstract][Full Text] [Related]
38. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Huffman JW; Szklennik PV; Almond A; Bushell K; Selley DE; He H; Cassidy MP; Wiley JL; Martin BR Bioorg Med Chem Lett; 2005 Sep; 15(18):4110-3. PubMed ID: 16005223 [TBL] [Abstract][Full Text] [Related]
39. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Onaivi ES Neuropsychobiology; 2006; 54(4):231-46. PubMed ID: 17356307 [TBL] [Abstract][Full Text] [Related]
40. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain. Sain NM; Liang A; Kane SA; Urban MO Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]